September 17, 2018

Tropichem, which specializes in complex drug product formulation and manufacturing of veterinary pharmaceutical products, is expanding its North American manufacturing capabilities, adding a non-sterile liquid facility for production of anti-parasiticide spot-ons and other registered product categories. The company’s Montreal location was chosen based on the company’s March 2018 acquisition of Tetragenx, leveraging the existing validation batch scale manufacturing for product development and technical transfers.

“When we acquired Tetragenx six months ago, we created a CDMO and outlined a manufacturing strategy to address unmet needs in the Animal Health industry,” said John Kane, CEO of Tropichem. “This investment is our first step toward our goal of becoming the industry’s leading CDMO.”

Commercial production will commence in January 2019, and additional investments for other dosage forms will be announced later this year.

Share This Story On:

Stockroom //
New Products

Digital Guide

CBD Trends

This digital guide provides valuable information on the subject of CBD, including content on dosage and the importance of being fully transparent about the product’s origin

Dog & Cat Needs

With dogs and cats being members of the family, there's vital information to know in order to serve their pet parents.

Pet Health

This digital guide describes a variety of health issues and the ways that pet parents can care for their pet's well-being through pet supplements..

Pet Nutrition

Discover how science, technology and pet owning lifestyles are changing the industry.

Pet Parenting

This digital guide dives into the human-animal bond, and the roles that pet parents play in the development of their companion animals.

Pet Supplements

This digital guide provides valuable information on the subject of pet supplements, including details on the NASC and how brands should earn consumer trust.

Enews Subscribe

Subscribe To Pet Age
Sign up for the weekly e-newsletter, print magazine and more. Sign Up